Intratumoral INT230-6 (cisplatin, vinblastine, shao) alone or with ipilimumab prolonged survival with favorable safety in adults with refractory sarcomas.
Bibliographic record
Abstract
11568 Background: Sarcomas are a rare and diverse group of solid tumors from mesenchymal cells; chemotherapy provides limited benefit for metastatic disease. INT230-6 is a novel formulation of cisplatin (CIS), vinblastine (VIN) and a tissue dispersion enhancer (SHAO) designed for intratumoral (IT) delivery. The drug diffuses into cancer cells, causes apoptosis and recruits dendritic and T-cells to the tumor. Adding ipilimumab (IPI) appears to improve INT230-6 responses in models and clinically. The study evaluated INT230-6 for safety and efficacy alone and with intravenous (IV) IPI. Previously reported results showed INT230-6 alone induced tumor regression, T-cell influx and abscopal effects in uninjected lesions1,2. Methods: IT-01 is an open-label phase1/2 study in adults with locally advanced, unresectable or metastatic solid tumors, including sarcoma. INT230-6 dose was set by tumor diameter or volume. INT230-6 was dosed IT Q2W for up to 5 doses alone or with IPI at 3mg/kg Q3 weeks for 4 doses. Maintenance INT230-6 dosing was Q9W. Results: The study enrolled 29 sarcoma patients with 11 subtypes (mainly leiomyosarcoma, liposarcoma, pleomorphic, chondrosarcoma and chordoma). The maximum INT230-6 dose at a single visit was 175 mL (87.5 mg of CIS, 17.5 mg VIN) in 1 or more tumors, an amount that exceeds an IV dose of VIN or CIS. PK analysis shows that >95% of VIN stays in the tumor. The >20% treatment-related adverse events (TRAEs) in evaluable monotherapy patients (n=15) were localized pain (80%), nausea (40%), fatigue (33%), decreased appetite (27%), and vomiting (20%). The >20% TRAEs in evaluable IPI/INT230-6 patients (n=14) were fatigue (39%), localized pain (39%), nausea (31%), pruritus (23%), rash (23%) and vomiting. G3 TRAEs occurred in 20% and 7% of patients in the INT230-6 and combination arms respectively with no grade 4 or 5 events in either arm. RECIST metrics are confounded by IT injections due to the large volume of highly retained INT230-6 and the influx of immune infiltrates. Analysis of median overall survival (mOS) for INT230-6 alone (n=15) was 649 days. For INT230-6 dosed at a volume/total tumor burden (TTB) ratio of ≥40%, the mOS was 715 days. The mOS of the combination has not been reached with over 1 year of median follow-up. OS data compare favorably to a synthetic control (mOS of 205 days) based on historical data3. The hazard ratios of INT230-6 alone or with IPI for OS to the synthetic control were 0.446 and 0.270, p-values <0.01. Conclusions: INT230-6 dosed IT alone or with IPI was well-tolerated in diverse sarcomas. INT230-6 use was associated with immune infiltration and favorable mOS as compared to a synthetic control, particularly when ≥40% of the TTB was injected. A randomized phase 3 trial vs. SOC in selected sarcoma subtypes with an OS endpoint is planned. References: 1. Oncoimmunology. 2019 Jul 16;8(10). 2. ASCO 6/2022. 3. Sci Rep. 2016;6:35448. Clinical trial information: NCT03058289 .
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".